Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
Cedars-Sinai Medical Center
150 participants
Jul 30, 2018
INTERVENTIONAL
Summary
This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.
Eligibility
Inclusion Criteria2
- Healthy Volunteers: male or female ≥ 18 years of age with a BMI<30, with no history of cardiovascular disease
- Patients: Medically stable, male or female ≥ 18 years of age who is have not suspected of having or has been diagnosed with coronary artery disease and undergone stenting or bypass surgery
Exclusion Criteria6
- Contraindications to MR imaging including mechanically, magnetically, or electrically activated implants, ferromagnetic implants and ferromagnetic foreign bodies, pregnancy.
- Inability to tolerate MR imaging secondary to an inability to hold breath for a short time or have claustrophobia.
- Non-compliant with visit instructions, including following procedure instructions
- Severe allergy to animal dander or animal-instigated asthma
- Specific to gadolinium-based contrast agents: Renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR <45ml/min) or previous allergic reaction to gadolinium-based contrast agents.*
- Volunteers who have had four or more prior previous gadolinium contrast scan
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03504956